Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary (2010)
Chapter: Appendix A: Workshop Agenda
Appendix A
Workshop Agenda
National Cancer Policy Forum
Workshop on Extending the Spectrum of
Precompetitive Collaboration in Oncology Research
The Keck Center of The National Academies
500 Fifth Street, NW, Room 100
Washington, DC 20001
DAY 1: TUESDAY, FEBRUARY 9, 2010
|
8:00 am |
Registration and Continental BreakfastRegistration and Continental Breakfast |
|
8:30 am |
Welcome from National Cancer Policy Forum and Overview of the Workshop John Wagner, M.D., Ph.D., Merck & Co., Inc., Workshop Chair |
|
8:45 am |
General Characterization of the Precompetitive Collaboration Environment Session Chair: John Wagner, M.D., Ph.D., Merck & Co., Inc. |
|
|
Open Innovation Networks Between Academia and Industry Neal Cohen, M.D., M.P.H., M.S., University of California–San Francisco School of Medicine |
|
|
Overview of Precompetitive Collaboration with Exemplar Models Jill Altshuler, M.B.A., AltshulerGray |
|
|
Open Access Integrative Bionetworks Stephen Friend, M.D., Ph.D., Sage Bionetworks |
|
|
PatientsLikeMe James Heywood |
|
|
Panel Discussion and Audience Polling: 30 Minutes |
|
11:15 am |
Break |
|
11:30 am |
Precompetitive Collaboration in Science Session Chair: John Wagner, M.D., Ph.D., Merck & Co., Inc. |
|
|
SEMATECH William Spencer, Ph.D. |
|
|
Science Commons Thinh Nguyen, J.D. |
|
|
Panel Discussion: 20 Minutes |
|
12:30 pm |
Lunch |
|
1:30 pm |
Precompetitive Collaboration in Biomedicine Session Chair: Stephen Friend, M.D., Ph.D., Sage Bionetworks |
|
|
The Biomarkers Consortium David Wholley, M. Phil., Foundation for the National Institutes of Health |
|
|
Critical Path Institute Raymond Woosley, M.D., Ph.D. |
|
|
Breakthrough Innovation Bernard Munos, M.B.A., Ph.D., Eli Lilly and Company |
|
|
Precompetitive Informatics Initiatives in Drug Discovery Bryn Williams-Jones, Pfizer |
|
|
Panel Discussion: 30 Minutes |
|
3:45 pm |
Break |
|
4:00 pm |
Day 1 Concluding Thoughts Open-Source Science Karim R. Lakhani, Ph.D., M.S., Harvard Business School |
|
|
Discussion and Audience Polling: 30 minutes |
|
5:00 pm |
Adjourn Day 1 |
DAY 2: WEDNESDAY, FEBRUARY 10, 2010
|
8:00 am |
Registration and Continental Breakfast |
|
8:30 am |
Thoughts on Day 1 and Report Back from Dinner Discussion |
|
8:45 am |
Precompetitive Collaboration in Oncology Session Chair: Stephen Eck, M.D., Ph.D., Eli Lilly and Company |
|
|
I-SPY 2 TRIAL Laura Esserman, M.D., M.B.A., UCSF Carol Franc Buck Breast Care Center |
|
|
The Cancer Genome Atlas Joseph Vockley, Ph.D., National Cancer Institute |
|
|
Merck, AstraZeneca Drug Combination Pearl Huang, Ph.D., Merck & Co., Inc. |
|
|
CEO Roundtable on Cancer’s Life Sciences Consortium Gregory Curt, M.D., AstraZeneca |
|
|
Imaging Studies Gary Kelloff, M.D., National Cancer Institute1 |
|
|
Panel Discussion: 30 Minutes |
|
11:30 am |
Break—Pick Up Boxed Lunches and Return for Final Session |
|
11:45 am |
Lessons Learned and Future Directions for Precompetitive Collaboration in Oncology Session Chair: John Wagner, M.D., Ph.D., Merck & Co., Inc. |
|
|
Opening Remarks Mark McClellan, M.D., Ph.D., Brookings Institution’s Engelberg Center for Health Care Reform |
|
|
Panelists: Jill Altshuler, M.B.A., AltshulerGray Neal Cohen, M.D., M.P.H., M.S., University of California–San Francisco School of Medicine Stephen Eck, M.D., Ph.D., Eli Lilly and Company Mark McClellan, M.D., Ph.D., Brookings Institution’s Engelberg Center for Health Care Reform Raymond Woosley, M.D., Ph.D., Critical Path Institute |
|
1:30 pm |
Adjourn Day 2 |
